Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fsd Pharma Inc Cl B (CSE: HUGE )

0.1250 UNCHANGED
Last Price Updated: 3:58 PM EDT, Aug 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fsd Pharma Inc Cl B

< Previous 1 2 3 4 5 6 7 8 9 Next >
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Shareholders Approve Plans for Share Consolidation, Name Change
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Reports on Status of New Product, Investment in Celly Nutrition Corp.
Via Investor Brand Network
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development Team
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Revolutionary Rapid Detoxification Drink Spotlighted in 24/7 Market News Report
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Holds Annual General and Special Meeting of Shareholders, Reports on Voting Results
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness
Via Investor Brand Network
FSD Pharma provides Corporate Update
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Awarded Final Judgment, Confirmation of $3M-Plus Arbitration Award
Via Investor Brand Network
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
Via ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
Via Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
Via Investor Brand Network
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Signs Option Agreement with USC to Exclusively Evaluate Novel Technology for Commercialization
Via Investor Brand Network
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces IRB Approval for Acute Alcohol Intoxication Study
Via Investor Brand Network
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
Via ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Wins Petition, Awards for Damages and Fees
Via Investor Brand Network
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
Via ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
Via Investor Brand Network
MiningNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
Via Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency
Via Investor Brand Network
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
Via ACCESSWIRE
FSD Pharma Provides Corporate Update
Via ACCESSWIRE
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
Via ACCESSWIRE
TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
Via Investor Brand Network
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
Via ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
Via Investor Brand Network
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.